ASOs that restore the parkin protein, gene therapy to induce enzymes required for dopamine biosynthesis or reduce the activity of dopamine degrading enzyme, siRNA which reduce SNCA mRNA levels, short hairpin RNAs that knockdown α-synuclein, miRNA-7, miRNA-153, miRNA-214; which in turn downregulate α-synculein expression and aptamers selectively binding to α-synuclein are some other NBTs for therapeutic management of Parkinson’s. This evidence concerns the gene SNCA and Parkinsonism.